Select Page
Responsive Centered YouTube Video
Insights on treatment protocols and challenges in addressing reinfections in long Covid patients.
  • Introduction to the challenges of treating long Covid patients with persistent symptoms. 0:33
  • Dr. Paul Merrick’s experience in developing early treatment protocols for Covid-19. 1:02
  • Discussion on the complexity of Covid-19 pathophysiology and the role of the spike protein. 16:02
  • Importance of addressing coagulation issues in acute, long Covid, and vaccine-injured patients. 17:39
  • Focus on the management of coagulation aspects in Covid-19 for effective treatment. 18:09
  • Exploration of treatment protocols by FLCCC and their role in early treatment strategies. 19:05
  • Addressing reinfections in long Covid patients and strategies to tackle brain infections. 19:22
Exploration of physical properties of blood cells in relation to long-term consequences of COVID-19.
  • Physical phenotyping involves probing the mechanical features of cells to extract internal information. 33:03
  • Application of mechanical probing on single blood cells to understand their development and differentiation. 34:05
  • Hematopoietic stem cells differentiate into various blood cell types with distinct internal structures. 35:05
  • Differences in microtubule organization between precursor cells and mature neutrophils can be measured through deformability. 36:03
Investigation into altered blood cell properties in post-COVID patients reveals potential mechanisms for thrombosis.
  • Physical properties of blood cells are altered in post-COVID patients, with red blood cells showing the most severe changes. 36:31
  • New nephritic techniques allow for high-speed measurement of cell deformability, enabling potential clinical applications. 41:15
  • Research indicates that recovered post-COVID patients still exhibit altered blood cell properties, possibly linked to long COVID symptoms. 50:56
  • Collaboration with ophthalmologists and researchers studying auto antibodies against receptors may provide insights into reduced blood flow in post-COVID patients. 54:11
Discussion on thrombosis in COVID-19 patients, highlighting factors like endothelial injury, hypercoagulability, and turbulent blood flow.
  • Endothelial injury, hypercoagulability, and turbulent blood flow are key factors in thrombosis. 1:07:19
  • Factors such as viremia of SARS-CoV-2, autoantibodies, and spike protein contribute to hypercoagulability. 1:09:58
  • Hypoxia can lead to vasoconstriction, hypertension, and subsequent endothelial injury. 1:12:06
Insights on thrombosis development in long Covid patients and potential therapies.
  • Endothelial damage activates contact pathway leading to thrombus formation. 1:13:22
  • Antibody interaction with SARS-CoV-2 spike protein can drive contact pathway activation. 1:13:35
  • Defective fibrinolysis contributes to thrombus persistence and tissue damage. 1:14:14
  • Reduced levels of protein C in patients with long Covid lead to enhanced clotting. 1:15:56
  • Neutrophil elastase can split spike protein into peptides that drive clotting. 1:16:45
  • Cytokines released by immune cells contribute to endothelial damage and thrombus formation. 1:19:00
  • Therapies include thrombopreventive drugs and thrombolytic agents to address clotting issues. 1:23:05
  • Clinical trials explore the use of activated protein C to manage thrombosis in long Covid patients. 1:24:30
  • Proposed concept involves adding additional constituents to heparin in apheresis for enhanced virus neutralization. 1:25:07
  • Natural products show promise in lysing clots with potential for low side effects. 1:27:42
Overview of therapeutic apheresis in immune system disorders and its potential role in long COVID.
  • Dr. Kiprov is the chief of the Division of Immunotherapy at California Pacific Medical Center. 1:41:04
  • Dr. Kiprov’s experience spans over a quarter of a century in therapeutic apheresis. 1:41:27
  • He has served on the American Society of Apheresis board of directors. 1:41:33
  • He has published extensively on therapeutic apheresis and immune system disorders. 1:41:33
  • He is involved in stem cell therapies and vaccine trials. 1:41:55
  • Dr. Kiprov is an expert in therapeutic apheresis for immune system disorders. 1:42:03
  • Dr. Kiprov’s work focuses on fostering immune system health and longevity. 1:42:10
  • He focuses on combining healthy eating habits and physical therapies for immune system health. 1:42:10
  • His unique approach includes a cookbook on boosting the immune system and preventing disease. 1:42:18
  • Therapeutic apheresis involves removing blood components like plasma for treatment. 1:43:02
Overview of technologies and procedures used in treating various diseases like Long Covid.
  • Historical background on bloodletting and the evolution of apheresis technology. 1:43:10
  • Introduction to therapeutic apheresis and its applications in removing specific blood components. 1:47:03
  • Explanation of double filtration technology for removing targeted components from plasma. 1:51:22
  • Discussion on the complex procedure of heparin-induced extracorporeal LDL precipitation. 1:53:59
  • Comparison of therapeutic plasma exchange using centrifugal devices as a safer and cost-effective option. 1:56:04
  • Impact of therapeutic apheresis on inflammatory factors and coagulation in diseases like Long Covid. 1:57:06
  • Evidence of phenotypic changes in T cells and proteomic effects through therapeutic plasma exchange. 1:58:07
  • Observations on cell subset alterations and improvements in patients with Long Covid post-treatment. 1:59:04
  • Case study demonstrating rapid improvement in lung function and overall health post-apheresis treatment. 2:01:15
  • Discussion on post-infection immune dysregulation leading to various chronic conditions and similarities in pathogenesis. 2:03:06
  • Insights on personalized treatment for Long Covid patients using plasma exchange and immunomodulatory therapy. 2:03:40
  • Patients with Long Covid exhibit autoantibodies, high inflammatory markers, and coagulation abnormalities. 2:03:40
  • Post-infection and post-vaccination autoimmune syndromes, including antiphospholipid syndrome, are observed. 2:04:10
  • Plasma exchange is used to remove cytokines, autoantibodies, immune complexes, and amyloid in Long Covid patients. 2:06:25
  • Stratification of patients based on cytokines, inflammation, autoantibodies, and coagulation status is crucial for treatment success. 2:15:01
  • Patients find clinics through publications and internet, seeking personalized treatment for Long Covid. 2:17:04
  • Predictors for successful treatment outcomes in plasma exchange or help apheresis are still under investigation. 2:20:07
Insights on diverse mechanisms and individualized treatments for long COVID patients.
  • Patients with long COVID exhibit individual responses to therapies, requiring personalized treatment. 2:20:55
  • Challenges in understanding why some patients respond dramatically to a therapy while others do not. 2:21:14
  • Long COVID and post-vaccine injuries show significant individual variation in treatment responses. 2:21:58
  • Plasma exchange may provide temporary relief but sustained cure for long COVID remains elusive. 2:23:27
  • Autoantibodies in vaccinated patients may lead to unexpected severe outcomes, such as sudden cardiac arrest. 2:27:30
  • Raised IgE levels and diverse mechanisms like bacteriophage activity and gut toxins play a role in long COVID. 2:31:05
  • Immune complexes, complement cascade, and endothelial damage are potential pathways for severe outcomes in long COVID patients. 2:34:01
  • Direct viral effects on pacemaker cells and thrombus formation in coronary arteries may contribute to sudden cardiac events in long COVID. 2:35:02
  • Autopsy and further research are crucial to understand the underlying pathology of severe outcomes in long COVID patients. 2:35:39
Insights on autoimmune response, spike protein, and diverse antibodies in Long Covid patients.
  • Long Covid linked to autoimmune response triggered by spike protein. 2:36:20
  • Presence of diverse antibodies in Long Covid and post-vaccine injury cases. 2:47:02
  • Concerns raised about the quality control and diversity of mRNA in vaccines. 2:47:52
  • Proposed layered approach for interventions in managing Long Covid. 2:50:06
Discussion on the importance of addressing diet, viral reservoirs, and long-term solutions for long Covid.
  • Patients often overlook the impact of diet on their health, which can exacerbate symptoms. 2:52:08
  • Nutraceuticals like curcumin and black seed oil show promise in improving outcomes for long Covid. 2:52:31
  • Long Covid may involve viral reservoirs in the body, such as gut crypts and sinuses, contributing to persistent symptoms. 3:04:00
  • Addressing viral hideouts and viral sources is crucial for eradicating the virus and reducing symptom recurrence. 3:05:31
Insights and recommendations from experts on addressing long Covid and thrombosis
  • Individualized approach crucial for long Covid treatment based on patient presentation. 3:07:29
  • Importance of identifying primary immune triggers in long Covid symptoms. 3:07:57
  • Focus on restoring tight junction integrity in the gut to address autoimmune diseases. 3:09:00
  • Need for personalized treatment plans for long Covid patients due to varied presentations. 3:11:20
  • Emphasis on finding the underlying cause (‘fire’) of symptoms in long Covid for effective treatment. 3:14:04
  • Call for collaboration, research, and treatment development for long Covid patients. 3:18:33
  • Urgent need to shift focus towards treatment rather than observation in long Covid research. 3:22:07
Cutting-edge breakthrough thinking on Long Covid Coalition Congress findings.
  • Importance of combining knowledge for patient care. 3:23:10
  • Acknowledgment of organizers’ efforts in bringing experts together. 3:23:24
  • Recognition of experts’ global expertise. 3:23:52
  • Appreciation for coalition’s efforts in organizing the event. 3:23:58
  • Wishes for a good evening to all participants. 3:24:04